A multicenter, phase II single-arm study of Anlotinib combined with Sintilimab in the second-line treatment of squamous non-small cell lung cancer
Latest Information Update: 01 Dec 2020
At a glance
- Drugs Catequentinib (Primary) ; Sintilimab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Dec 2020 New trial record